Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma CatabolismGlobeNewsWire • 06/16/22
Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewsWire • 06/01/22
European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals' CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract CancerGlobeNewsWire • 05/24/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFLPRNewsWire • 03/26/22
The Law Offices of Frank R. Cruz Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of InvestorsBusiness Wire • 03/11/22
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of InvestorsBusiness Wire • 03/10/22
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of InvestorsBusiness Wire • 03/09/22
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Rafael Holdings, Inc. (RFL) on Behalf of InvestorsBusiness Wire • 03/08/22
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Rafael Holdings, Inc. (RFL) on Behalf of InvestorsBusiness Wire • 03/07/22
The Law Offices of Frank R. Cruz Announces Investigation of Rafael Holdings, Inc. (RFL) on Behalf of InvestorsBusiness Wire • 03/07/22
William “Bill” Conkling to assume the role of Chief Executive Officer as of February 1, 2022GlobeNewsWire • 01/21/22
Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract CancerGlobeNewsWire • 01/18/22
Rafael Pharmaceuticals Announces Successful Completion of Dose Escalation with No Dose-Limiting Toxicity (DLT) in First Cohort of APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell SarcomaGlobeNewsWire • 01/06/22
Rafael Holdings Reports First Quarter Fiscal 2022 Financial and Operating ResultsGlobeNewsWire • 12/15/21
Rafael Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) From Phase 2 Clinical Trial for Refractory Burkitt Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting and ExpositionGlobeNewsWire • 12/13/21
Rafael Holdings Realigns Leadership Team to Support Earlier Stage Pipeline FocusGlobeNewsWire • 11/22/21
Rafael Pharmaceuticals Announces First Patient Enrolled in APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell SarcomaGlobeNewsWire • 11/11/21
European Medicines Agency Grants Orphan Drug Designation to Rafael Pharmaceuticals' CPI-613® (Devimistat) for Treatment of Patients with Relapsed or Refractory Burkitt's LymphomaGlobeNewsWire • 11/03/21
Rafael Holdings stock plummets after cancer-treatment trial missed primary endpointMarket Watch • 10/28/21
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation into the Fairness of the Merger of Rafael Holdings, Inc. with Rafael Pharmaceuticals, Inc.Newsfile Corp • 10/18/21
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2021 Financial and Operating Results and Provides Business UpdateGlobeNewsWire • 10/18/21
